| Id: | acc2249 |
| Group: | 2sens |
| Protein: | RB1 |
| Gene Symbol: | RB1 |
| Protein Id: | P06400 |
| Protein Name: | RB_HUMAN |
| PTM: | phosphorylation |
| Site: | Thr356 |
| Site Sequence: | SIDSFETQRTPRKSNLDEEVN |
| Disease Category: | Cancer |
| Disease: | Head and Neck Cancer |
| Disease Subtype: | HNSCC |
| Disease Cellline: | SCC61 |
| Disease Info: | |
| Drug: | palbociclib(CDK4/6 inhibitors) |
| Drug Info: | "Palbociclib is a selective oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with endocrine therapies such as aromatase inhibitors or fulvestrant. " |
| Effect: | modulate |
| Effect Info: | "When receiving surgery or surgery plus radiotherapy, the median survival time of tumor patients with low pT356RB1 levels is almost four times that of patients with high pT356RB1 expression." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 26265441 |
| Sentence Index: | 26265441_1-2 |
| Sentence: | "Locally advanced squamous cell carcinoma of the head and neck (SCCHN) that is not associated with human papillomavirus (HPV) has a poor prognosis in contrast to HPV-positive disease. To better understand the importance of RB1 activity in HPV-negative SCCHN, we investigated the prognostic value of inhibitory CDK4/6 phosphorylation of RB1 on threonine 356 (T356) in archival HPV-negative tumor specimens from patients who underwent surgical resection and adjuvant radiation." |
Sequence & Structure:
MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMDTSNKEEK
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| RB1-Thr356 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | -0.816 |
| HGSC | 0.881 |
| ccRCC | |
| GBM | -0.914 |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | 0.85 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 356 | U | Ovarian cancer/carcinoma | Phosphorylation | 28319064 |
| T | 356 | U | Squamous cell carcinoma | Phosphorylation | 26265441 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Staursporin | 6.3161 | down | |
| P06400 | RB1 | P | Thr356 | LFLDHDKTLQTDSIDSFETQRT(ph)PR | A549 | Staursporin | 6.4743 | down | |
| P06400 | RB1 | P | Thr356 | LFLDHDKTLQTDSIDSFETQRT(ph)PR | A549 | Dasatinib | 8.7153 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | K562 | Paclitaxel | 7.5238 | - | |
| P06400 | RB1 | P | Thr356 | LFLDHDKTLQTDSIDSFETQRT(ph)PR | K562 | Paclitaxel | 8.7492 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Tideglusib | 7.7718 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Refametinib | 6.9355 | - | |
| P06400 | RB1 | P | Thr356 | LFLDHDKTLQTDSIDSFETQRT(ph)PR | A549 | Refametinib | 8.7832 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Pictilisib | 5.7612 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | PD325901 | 9.0731 | - | |
| P06400 | RB1 | P | Thr356 | LFLDHDKTLQTDSIDSFETQRT(ph)PR | A549 | Nintedanib | 5.2492 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Dasatinib | 5.0787 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Dasatinib | 7.2207 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Afatinib | 8.4298 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | AZD8055 | 8.8775 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Gefitinib | 6.7699 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Gefitinib | 5.4291 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Gefitinib | 7.5513 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Gefitinib | 2 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Dasatinib | 6.0442 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Dasatinib | 2 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Dasatinib | 5.5741 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Dasatinib | 5.7699 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Afatinib | 8.6577 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Afatinib | 6.6511 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Afatinib | 2 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
